ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2677

Disease Progression Into Adulthood In Patients With Juvenile Idiopathic Arthritis – a Longitudinal 30 Year Follow-Up Study

Anne Marit Selvaag, Hanne Aulie, Vibke Lilleby and Berit Flatø, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: juvenile idiopathic arthritis (JIA), longitudinal studies and remission

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The aim of the study was to assess disease activity and health status in a previously studied cohort of patients with juvenile idiopathic arthritis (JIA) 30 years after disease onset and reveal predictors of active disease. 

Methods:

A total of 254 patients with JIA, first referred to our hospital from 1980 to1985, were reexamined clinically after median 15 years of disease duration, and by mailed questionnaires after median 23 years. These patients were invited to attend the present study. All patients were assessed by questionnaires, and those with signs of active disease after 15, 23 and/or 30 years were invited to a clinical reexamination. Health status was measured by HAQ and SF-36, and disease activity by the clinical version of the juvenile arthritis disease activity score (cJADAS). Logistic regression analyses were used to assess predictors of persistently active disease and an unacceptable symptom state (cJADAS > 4.5).

Results:

One hundred and seventy-one patients (67%) were included in the study. They were examined after a median of 30 (range 21-40) years of disease duration, median age 39 (range 28-45) years, 74% females.

              After 30 years, 101 patients (59%) were in clinical remission off medication, 12 (7%) were in remission on medication and 58 (34%) had persistently active disease. Thirty-seven of 57 patients (65%) with active disease at 15 years follow-up had active disease at 30 years follow-up, and 20 patients (35%) went into remission on/off medication. Eighty-four of 97 patients (87%) in remission off medication at 15 years were in remission at 30 years follow-up. Patients in remission on medication at 15 years (n=17) tended to flare (n=9) or go into remission off medication (n=6).

The cJADAS score was median 1.9 for the total study group, and 43% (n=73) of the patients had a cJADAS score ≤ 1.0, 10 % (n=16) had cJADAS from 1.1 to 2.0, 18% (n=30) had cJADAS from 2.1 to 4.5, and 30% (n= 50) had cJADAS > 4.5.

Predictors of persistently active disease at 30 years follow-up were: being diagnosed with a JIA subgroup other than persistent oligo articular and systemic JIA (OR 4.1, 95%CI 1.5-11.5), being DR1 positive (OR 8.3, 95%CI 2.3-30.3), a short total time in remission (OR 9.0, 95% CI 3.0-26.7), and not being in remission at 15 years follow-up (OR 13.7, 95%CI 4.9-38.4). R²=65%. Predictors of a cJADAS score > 4.5 at 30 years follow-up were physician’s global score of disease activity at 15 years (OR 2.4, 95%CI 1.7-3.5) and daily smoking (OR 2.5, 95%CI 1.1-5.9). R²=23%.

We compared disease activity at 15 years with that of 30 years follow-up for 90 patients. There were significant improvements in physicians global assessment of disease activity (p=0.003), number of active joints (p=0.010), ESR (p=0.041) and CRP (p<0.001), but no significant change in patient’s global assessment, number of joints with limitation of motion, HAQ, or SF-36.

Conclusion: The overall remission rates were stable between 15 and 30 years. After 30 years, a third of the JIA patients had an unacceptable symptom state and a third was not in remission on or off medication. Physician’s assessment of disease activity and inflammatory markers improved over the years, but patient reported disability and health status did not change.


Disclosure:

A. M. Selvaag,

The Norwegian Women’s Public Health Association,

2;

H. Aulie,
None;

V. Lilleby,
None;

B. Flatø,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-progression-into-adulthood-in-patients-with-juvenile-idiopathic-arthritis-a-longitudinal-30-year-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology